Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 9/20 | 0.40 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255916 | 1.00 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11AAK1 | |
| SCHEMBL2544105 | 0.86 | AAK1 (0.39) | MAPK14MAPK13MAPK12MAPK11AAK1 | |
| SCHEMBL2544106 | 0.86 | AAK1 (0.39) | MAPK14MAPK13MAPK12MAPK11AAK1 | |
| SCHEMBL2547393 | 0.86 | MAPK14 (0.37) | MAPK14MAPK13MAPK12MAPK11CACNA1B | |
| SCHEMBL18203963 | 0.83 | AAK1 (0.44) | MAPK14AAK1 | |
| SCHEMBL18203964 | 0.83 | AAK1 (0.44) | MAPK14AAK1 | |
| SCHEMBL560396 | 0.82 | CACNA1B (0.38) | MAPK14MAPK13MAPK12MAPK11AAK1 | |
| SCHEMBL560395 | 0.82 | CACNA1B (0.38) | MAPK14MAPK13MAPK12MAPK11AAK1 | |
| SCHEMBL12234610 | 0.82 | MAPK14 (0.41) | MAPK14MAPK13MAPK12MAPK11CACNA1B | |
| SCHEMBL22641461 | 0.81 | MAPK14 (0.40) | MAPK14MAPK13MAPK12MAPK11CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013175-B9 | p38 MAP KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2020-11-11 | — | — | EP | disclosed |
| EP-2013175-B1 | p38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2016-11-09 | — | — | EP | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
| WO-2007129040-A1 | p38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099185-A1 | P38 Map Kinase Inhibitors | MAPK1, CNKSR1, MAPK3 | MAPK14 15/4885MAPK13 6/4885MAPK12 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.